Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2018 October;66(5) > Minerva Cardioangiologica 2018 October;66(5):646-58

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Cardioangiologica 2018 October;66(5):646-58

DOI: 10.23736/S0026-4725.18.04673-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

The Synergy stent in high-bleeding risk patients: why design matters

Mauro CHIARITO 1, 2, Davide CAO 1, 2, Francesco CANNATA 1, 2, Cristina PANICO 1, 2, Bernhard REIMERS 1, 2, Giulio G. STEFANINI 1, 2

1 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 2 Cardiology Center, Humanitas Research Hospital, Rozzano, Milan, Italy



Antithrombotic management after percutaneous coronary intervention is based on dual antiplatelet therapy (DAPT), that has unequivocally shown to reduce the risk of recurrent ischemic events at cost of an important risk of bleeding. In order to balance ischemic and bleeding risks, DAPT duration should be based on patients and lesions features as well as stent type. Based on these considerations, patients at high bleeding risk (HBR) undergoing PCI represent a challenging subgroup. The Synergy stent (Boston Scientific, Marlborough, MA, USA) is a new-generation everolimus-eluting stent with a biodegradable polymer coating, presenting several features that have the potential to reduce acute and long-term thrombogenicity and the subsequent need for DAPT. The aim of this manuscript is to review the evidence about the impact of stent design on the optimal antithrombotic strategy in HBR patients and the potential role of the Synergy BP-EES in this relevant population.


KEY WORDS: Hemorrhage - Percutaneous coronary intervention - Everolimus - Drug-eluting stents - Platelet aggregation inhibitors

top of page